4th Quarter - Amendment

BROWNSTEIN HYATT FARBER SCHRECK, LLP for NOVARTIS

Firm
Client
Income
$50,000
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report Jan 20, 2020 $50,000 Replaced
4th Quarter - Amendment (this page) Jul 8, 2020 $50,000 Yes

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Tax filing programs

LobbyistCovered position, as disclosed
RADHA MOHAN New —

Contacted: SENATE; Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR)

Medical/Disease Research/Clinical Labs MED

Issues related to cell and gene therapy Pharmaceutical pricing Issues related to the development of therapies for rare diseases

LobbyistCovered position, as disclosed
EMILY FELDER —

Contacted: SENATE; U.S. Trade Representative (USTR); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES

Health Issues HCR

Issues related to cell and gene therapy Pharmaceutical pricing Issues related to the development of therapies for rare diseases

LobbyistCovered position, as disclosed
NADEAM ELSHAMI —
MARC LAMPKIN —
BRIAN MCKEON —
JEROME MURRAY —
ZACHARY PFISTER —
BRIAN WILD —

Contacted: HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Executive Office of the President (EOP); SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.